CJC-1295 (DAC)
This research compound combines a GHRH analog with a GHS receptor agonist for dual-pathway growth hormone axis investigation. The combination enables study of synergistic receptor activation across both the release and amplification arms of the GH signaling cascade. For research purposes only.
Weekdays before 2PM EST
With Every Batch
Tested in USA
Buy now, pay later with Afterpay, Klarna & Affirm
Research Overview
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) with a maleimidopropionic acid-DAC modification that extends its biological half-life by binding to serum albumin. This extended half-life (~6–8 days vs. minutes for native GHRH) makes it a significant research compound for studying prolonged GH axis stimulation.
Mechanism of Action
CJC-1295 DAC binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. The DAC conjugation enables albumin binding in circulation, dramatically extending its pharmacological activity. This results in sustained GH elevation and subsequent IGF-1 increase over multiple days from a single administration.
Experimental Applications
Studied in animal models for sustained growth hormone release kinetics, IGF-1 axis upregulation, age-related GH decline, body composition changes, sleep architecture effects, and pharmacokinetic profiling of long-acting GHRH analogs.
Compound Specifications
| Compound Type | Modified GHRH Analog (DAC-conjugated) |
| Purity | ≥ 99% |
| Appearance | White lyophilized powder |
| Storage | -20°C long-term; 2-8°C short-term |
| Testing Methods | HPLC, Mass Spectrometry |
| Packaging | Sealed sterile vial |
Certificate of Analysis
Lab Testing Notes
Each batch is third-party tested via HPLC (purity ?99%) and Mass Spectrometry (identity/MW confirmation). COA included with every order and available in our Research Library.
Mechanism of Action
CJC-1295 DAC binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. The DAC conjugation enables albumin binding in circulation, dramatically extending its pharmacological activity. This results in sustained GH elevation and subsequent IGF-1 increase over multiple days from a single administration.
Experimental Applications
Studied in animal models for sustained growth hormone release kinetics, IGF-1 axis upregulation, age-related GH decline, body composition changes, sleep architecture effects, and pharmacokinetic profiling of long-acting GHRH analogs.
Reconstitution Guidelines
Reconstitute with bacteriostatic water. Inject slowly along the inner vial wall. Swirl gently until dissolved — do not shake. Recommended: 1–2 mL per vial. Store at 2–8°C after reconstitution. Use within 30 days.
Related Peptides
Premium research peptides, lab-tested for purity
